Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer

Centre for Addiction and Mental Health8 enrolled

Overview

The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.

Subjects will receive a PET and MRI scan before and after treatment with phenelzine.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Major Depressive Disorder

Interventions

phenelzine treatmentOTHER

Subjects will have a PET and MRI scan before and after treatment with phenelzine.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18-80 years of age * good physical health * Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current major depressive episode (MDE) * DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a psychiatric consultation * greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale). * history of non-response to several different antidepressant classes Exclusion Criteria: * herbal, drug or medication use (that affect CNS function) * suicide attempts * drug or medication use within eight weeks (+5 half lives of medication) * history of substance abuse or any neurotoxin use * history of psychotic symptoms * history of central nervous system (CNS) medical illness * current substance abuse * test positive on pregnancy test (for women)

Locations (1)

Center for Addiction and Mental Health

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

MAO-B VT levels measured with PET in MDE secondary to MDD

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.